Anna Wald, M http://sildenafiluk.org .D., M.P.H., Lawrence Corey, M.D., Burkhard Timmler, M.D., Amalia Magaret, Ph.D., Terri Warren, M.N., Stephen Tyring, M.D., Ph.D., Christine Johnston, M.D., M.P.H., John Kriesel, M.D., Kenneth Fife, M.D., Ph.D., Lawrence Galitz, M.D., Susanne Stoelben, M.D., M.P.H., Meei-Li Huang, Ph.D., Stacy Selke, M.A., Hans-Peter Stobernack, D.V.M., Helga Ruebsamen-Schaeff, Ph.D., and Alexander Birkmann, Ph.D.1 These compounds, that have been developed three decades ago and are in widespread use today, ameliorate clinical disease.
The analysis was performed in accordance with Good Clinical Practice suggestions and the concepts of the Declaration of Helsinki, and the scholarly study protocol was approved by the relevant institutional review boards and regulatory agencies. The analysis was designed jointly by the study investigators and the sponsor . The investigators gathered the info, and the sponsor carried out the data analyses. All of the authors had complete access to the data and signed confidentiality agreements with the sponsor regarding the data. The initial draft of the manuscript was written by a medical article writer employed by the sponsor and was edited and revised by the initial author, with input from all the authors.